Achaogen, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2004-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.achaogen.com
Clinical Trials
25
Active:13
Completed:11
Trial Phases
3 Phases
Phase 1:22
Phase 2:1
Phase 3:2
Drug Approvals
1
FDA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (25 trials with phase data)• Click on a phase to view related trials
Phase 1
22 (88.0%)Phase 3
2 (8.0%)Phase 2
1 (4.0%)A Study to Assess the Effect of Plazomicin on the Pharmacokinetics of Metformin
- First Posted Date
- 2017-09-01
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT03270553
- Locations
- 🇺🇸
Clinical Site, Lincoln, Nebraska, United States
A Study to Assess the Metabolism, Excretion, and Mass Balance of Radio-Labeled Plazomicin
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: [14C]-plazomicin
- First Posted Date
- 2017-06-06
- Last Posted Date
- 2017-07-12
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT03177278
- Locations
- 🇺🇸
Clinical Site, Lincoln, Nebraska, United States
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Food Effect, and Drug-Drug Interaction Potential of ACHN-383 and ACHN-789
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- Drug: ACHN-383Drug: ACHN-789Drug: Placebo
- First Posted Date
- 2017-05-23
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03163550
- Locations
- 🇦🇺
Clinical Site, Perth, Australia
A Study of Plazomicin Compared With Meropenem for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP)
Phase 3
Completed
- Conditions
- Acute PyelonephritisComplicated Urinary Tract Infection
- Interventions
- First Posted Date
- 2015-07-01
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 609
- Registration Number
- NCT02486627
A Study of Plazomicin Compared With Colistin in Patients With Infection Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Phase 3
Completed
- Conditions
- Bloodstream Infections (BSI) Due to CREHospital-Acquired Bacterial Pneumonia (HABP) Due to CREVentilator-Associated Bacterial Pneumonia (VABP) Due to CREComplicated Urinary Tract Infection (cUTI) Due to CREAcute Pyelonephritis (AP) Due to CRE
- Interventions
- Drug: antibiotic of Investigator's choice
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2018-10-16
- Lead Sponsor
- Achaogen, Inc.
- Target Recruit Count
- 69
- Registration Number
- NCT01970371
- Prev
- 1
- 2
- 3
- Next
News
No news found